603087 甘李药业
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,245,00617.81%2,608,0371,712,2703,612,0443,361,882
减:营业总成本1,921,77216.77%2,306,6812,228,8692,021,7531,948,894
    其中:营业成本553,24114.97%697,421405,804396,111306,653
               财务费用(58,457)-14.64%(78,723)(94,294)(176,892)(574)
               资产减值损失17-100.50%(39,828)(79,043)(3,785)(3,167)
公允价值变动收益167,903-1,055.27%(17,916)(80,655)(54,455)(42,770)
投资收益55,851-6.67%63,33187,567140,08463,242
    其中:对联营企业和合营企业的投资收益------------
营业利润562,25877.25%315,286(568,873)1,698,9111,452,905
利润总额563,60581.21%306,141(582,473)1,696,0131,445,470
减:所得税费用56,33926.48%(34,090)(142,957)243,258214,760
净利润507,26590.36%340,231(439,516)1,452,7551,230,711
减:非控股权益-039.02%163-0-0-0
股东净利润507,26590.36%340,069(439,516)1,452,7551,230,711

市场价值指针
每股收益 (元) *0.85080.85%0.600-0.7802.5902.310
每股派息 (元) *0.500--0.200--0.3000.400
每股净资产 (元) *18.6456.63%18.08016.94618.10615.918
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容